Mitchell J. Waldran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Mitchell J. Waldran has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Adam Tully Waickman
Department of Microbiology and Immunology, SUNY Upstate Medical University
2 shared publications - Stephen James Thomas
Department of Microbiology and Immunology, SUNY Upstate Medical University, Syracuse, USA
2 shared publications Catherine Rexhouse
Department of Immunology & Microbial Disease, Albany Medical College , Albany, NY
1 shared publicationChad Gebo
Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA
1 shared publication- Chad Gebo
Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, New York, USA
1 shared publication Guillermo Herrera-Taracena
Janssen Global Public Health, Janssen Research and Development, Horsham, PA 19044, USA
1 shared publication
Latest Publications
- Open Access
- 7 June 2026
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (6)
Compensatory relationships determine the impact of TGF-β on the humoral immune response to hepatitis B surface antigen
Despite an effective vaccine against the hepatitis B virus (HBV), there are about 250 million people living with chronic HBV (CHB) worldwide and one million deaths annually. Most children and about 5% of adults exposed to HBV will fail to clear the virus, developing a lifelong infection. Hepatitis B surface antigen (HBsAg)-specific antibody (HBsAb) is protective in uninfected individuals and is considered a component of a functional cure. Immune factors that play important roles in regulating inflammation, such as TGF-β, IL-10, and regulatory T cells (Tregs), may also contribute to CHB pathogenesis. However, the early regulatory factors that promote HBsAg seroconversion are not well understood. To address this, we utilized adeno-associated virus (AAV)-mediated delivery of HBV (AAV-HBV) to mice. In this model, C57BL/6 mice fail to develop effective HBsAb responses, while BALB/c mice more efficiently seroconvert HBsAg. While inhibiting TGF-β, IL-10, or Tregs did not impact serum HBsAg levels in C57BL/6 mice, TGF-β depletion in BALB/c mice ablated the humoral response to HBsAg. Neutralizing IL-10, blocking CTLA-4, or depleting Tregs alone did not affect the HBsAb response in BALB/c mice. However, Treg depletion in the absence of TGF-β restored HBsAg clearance in an IL-10- and CTLA-4-independent manner. These findings highlight the immune balance regulated by TGF-β in the early adaptive response to an HBV antigen, as well as context-dependent compensatory interactions that may directly or indirectly impact antigen-specific humoral immunity.
- 7 June 2026
- Published by Oxford University Press (OUP) in The Journal of Immunology
- Vol. 215 (6)
Open AccessCompensatory relationships determine the impact of TGF-β on the humoral immune response to hepatitis B surface antigen
Despite an effective vaccine against the hepatitis B virus (HBV), there are about 250 million people living with chronic HBV (CHB) worldwide and one million deaths annually. Most children and about 5% of adults exposed to HBV will fail to clear the virus, developing a lifelong infection. Hepatitis B surface antigen (HBsAg)-specific antibody (HBsAb) is protective in uninfected individuals and is considered a component of a functional cure. Immune factors that play important roles in regulating inflammation, such as TGF-β, IL-10, and regulatory T cells (Tregs), may also contribute to CHB pathogenesis. However, the early regulatory factors that promote HBsAg seroconversion are not well understood. To address this, we utilized adeno-associated virus (AAV)-mediated delivery of HBV (AAV-HBV) to mice. In this model, C57BL/6 mice fail to develop effective HBsAb responses, while BALB/c mice more efficiently seroconvert HBsAg. While inhibiting TGF-β, IL-10, or Tregs did not impact serum HBsAg levels in C57BL/6 mice, TGF-β depletion in BALB/c mice ablated the humoral response to HBsAg. Neutralizing IL-10, blocking CTLA-4, or depleting Tregs alone did not affect the HBsAb response in BALB/c mice. However, Treg depletion in the absence of TGF-β restored HBsAg clearance in an IL-10- and CTLA-4-independent manner. These findings highlight the immune balance regulated by TGF-β in the early adaptive response to an HBV antigen, as well as context-dependent compensatory interactions that may directly or indirectly impact antigen-specific humoral immunity.
- 1 April 2024
- Published by Springer Nature in Nature Microbiology
- Vol. 9 (5) , 1356-1367
Low-dose dengue virus 3 human challenge model: a phase 1 open-label study
Dengue human infection models present an opportunity to explore the potential of a vaccine, anti-viral or immuno-compound for clinical benefit in a controlled setting. Here we report the outcome of a phase 1 open-label assessment of a low-dose dengue virus 3 (DENV-3) challenge model (NCT04298138), in which nine participants received a subcutaneous inoculation with 0.5 ml of a 1.4 × 103 plaque-forming unit per ml suspension of the attenuated DENV-3 strain CH53489. The primary and secondary endpoints of the study were to assess the safety of this DENV-3 strain in healthy flavivirus-seronegative individuals. All participants developed RNAaemia within 7 days after inoculation with peak titre ranging from 3.13 × 104 to 7.02 × 108 genome equivalents per ml. Solicited symptoms such as fever and rash, clinical laboratory abnormalities such as lymphopenia and thrombocytopenia, and self-reported symptoms such as myalgia were consistent with mild-to-moderate dengue in all volunteers. DENV-3-specific seroconversion and memory T cell responses were observed within 14 days after inoculation as assessed by enzyme-linked immunosorbent assay and interferon-gamma-based enzyme-linked immunospot. RNA sequencing and serum cytokine analysis revealed anti-viral responses that overlapped with the period of viraemia. The magnitude and frequency of clinical and immunologic endpoints correlated with an individual’s peak viral titre.
- 1 April 2024
- Published by Springer Nature in Nature Microbiology
- Vol. 9 (5) , 1356-1367
Low-dose dengue virus 3 human challenge model: a phase 1 open-label study
Dengue human infection models present an opportunity to explore the potential of a vaccine, anti-viral or immuno-compound for clinical benefit in a controlled setting. Here we report the outcome of a phase 1 open-label assessment of a low-dose dengue virus 3 (DENV-3) challenge model (NCT04298138), in which nine participants received a subcutaneous inoculation with 0.5 ml of a 1.4 × 103 plaque-forming unit per ml suspension of the attenuated DENV-3 strain CH53489. The primary and secondary endpoints of the study were to assess the safety of this DENV-3 strain in healthy flavivirus-seronegative individuals. All participants developed RNAaemia within 7 days after inoculation with peak titre ranging from 3.13 × 104 to 7.02 × 108 genome equivalents per ml. Solicited symptoms such as fever and rash, clinical laboratory abnormalities such as lymphopenia and thrombocytopenia, and self-reported symptoms such as myalgia were consistent with mild-to-moderate dengue in all volunteers. DENV-3-specific seroconversion and memory T cell responses were observed within 14 days after inoculation as assessed by enzyme-linked immunosorbent assay and interferon-gamma-based enzyme-linked immunospot. RNA sequencing and serum cytokine analysis revealed anti-viral responses that overlapped with the period of viraemia. The magnitude and frequency of clinical and immunologic endpoints correlated with an individual’s peak viral titre.
- 26 October 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (668) , eabo5019
Evolution of inflammation and immunity in a dengue virus 1 human infection model
Dengue virus (DENV) infections are major causes of morbidity and mortality throughout the tropics and subtropics. More than 400 million infections are estimated to occur every year, resulting in nearly 100 million symptomatic infections and more than 20,000 deaths. Early immune response kinetics to infection remain unclear, in large part due to the variable incubation period exhibited by the DENVs after introduction into a susceptible host. To fill this knowledge gap, we performed a comprehensive virologic and immunologic analysis of individuals experimentally infected with the underattenuated DENV-1 strain 45AZ5. This analysis captured both the kinetics and composition of the innate, humoral, and cellular immune responses elicited by experimental DENV-1 infection, as well as virologic and clinical features. We observed a robust DENV-specific immunoglobulin A (IgA) antibody response that manifested between the appearance of DENV-specific IgM and IgG in all challenged individuals, as well as the presence of a non-neutralizing/NS1-specific antibody response that was delayed relative to the appearance of DENV virion–specific humoral immunity. RNA sequencing analysis revealed discrete and temporally restricted gene modules that correlated with acute viremia and the induction of adaptive immunity. Our analysis provides a detailed description, in time and space, of the evolving matrix of DENV-elicited human inflammation and immunity and reveals several previously unappreciated immunological aspects of primary DENV-1 infection that can inform countermeasure development and evaluation.
- 26 October 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 14 (668) , eabo5019
Evolution of inflammation and immunity in a dengue virus 1 human infection model
Dengue virus (DENV) infections are major causes of morbidity and mortality throughout the tropics and subtropics. More than 400 million infections are estimated to occur every year, resulting in nearly 100 million symptomatic infections and more than 20,000 deaths. Early immune response kinetics to infection remain unclear, in large part due to the variable incubation period exhibited by the DENVs after introduction into a susceptible host. To fill this knowledge gap, we performed a comprehensive virologic and immunologic analysis of individuals experimentally infected with the underattenuated DENV-1 strain 45AZ5. This analysis captured both the kinetics and composition of the innate, humoral, and cellular immune responses elicited by experimental DENV-1 infection, as well as virologic and clinical features. We observed a robust DENV-specific immunoglobulin A (IgA) antibody response that manifested between the appearance of DENV-specific IgM and IgG in all challenged individuals, as well as the presence of a non-neutralizing/NS1-specific antibody response that was delayed relative to the appearance of DENV virion–specific humoral immunity. RNA sequencing analysis revealed discrete and temporally restricted gene modules that correlated with acute viremia and the induction of adaptive immunity. Our analysis provides a detailed description, in time and space, of the evolving matrix of DENV-elicited human inflammation and immunity and reveals several previously unappreciated immunological aspects of primary DENV-1 infection that can inform countermeasure development and evaluation.